CO4920249A1 - ANTAGONISTS OF AN IL-8 RECEPTOR - Google Patents

ANTAGONISTS OF AN IL-8 RECEPTOR

Info

Publication number
CO4920249A1
CO4920249A1 CO98003009A CO98003009A CO4920249A1 CO 4920249 A1 CO4920249 A1 CO 4920249A1 CO 98003009 A CO98003009 A CO 98003009A CO 98003009 A CO98003009 A CO 98003009A CO 4920249 A1 CO4920249 A1 CO 4920249A1
Authority
CO
Colombia
Prior art keywords
alkenyl
aryl
alkyl
4alkyl
heteroaryl
Prior art date
Application number
CO98003009A
Other languages
Spanish (es)
Inventor
Nie Hong
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4920249A1 publication Critical patent/CO4920249A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula:en la queR es -NH-C(X2 )-NH-(CR13 R14 )v -Z;Z es W, HET, , alquilo C1-10 opcionalmente sustituido, alquenilo C2-10 opcionalmente sustituido o alquinilo C2-10 opcionalmente sustituido;X es C(X1 )2 , O, N-R18 , C=O, ó S(O)m´ ;X1 es hidrógeno, halógeno, alquilo C1 -10 , NR4 R5 , C(O)NR4 R5 , alquilo C1-10 opcionalmente sustituido, alcoxi C1-10 , alcoxi C1-10 sustituido con halo, hidroxi, arilo, aril-alquilo C1-4 , ariloxi, aril-alquil C1-4 -oxi, heteroarilo, heteroarilalquilo, heterocíclico, heterocíclico- alquilo C1-4 o heteroaril-alquil C1-4 oxi;X2 es =O ó =S;A es CH2 , C(O) ó C(S);R1 se selecciona independientemente entre hidrógeno, halógeno, nitro, ciano, alquilo C1-10 sustituido con halo, alquilo C1-10 , alquenilo C2-10 , alcoxi C1-10 , alcoxi C1-10 sustituido con halo, azido, (CR8 R8 )q S(O)t R4 , hidroxi, hidroxi-alquilo C1-10 , arilo, aril-alquilo C1-4 , ariloxi, aril-alquil C1-4 -oxi, heteroarilo, heteroarilalquilo, heterocíclico, heterocíclico-alquilo C1-4 , heteroaril-alquil C1-4 -oxi, aril-alquenilo C2-10 , heteroaril-alquenilo C2-10 , heterocíclico-alquenilo C2-10 , (CR8 R8 )q NR4 R5 , alquenil C2-10 -C(O)-NR4 R5 , (CR8 R8 )q C(O)NR4 R5 , (CR8 R8 )q C(O)NR4 R10 , S(O)3 H, S(O)3 R8 , (CR8 R8 )q C(O)R11 , alquenil C2-10 -C(O)R11 , alquenil C2-10 -C(O)OR11 , C(O)R11 , (CR8 R8 )q C(O)OR12 , (CR8 R8 )q OC(O)R11 , (CR8 R8 )q NR4 C(O)R11 , (CR8 R8 )q-NHS(O)2 R17 ó (CR8 R8 )q S(O)2 NR4 R5 , o dos restos R1 en común pueden formar O-(CH2 )s -O- o un anillo saturado o insaturado de 5 a 6 miembros; y en que los anillos que contienen arilo, heteroarilo y heterocíclico pueden todos ellos estar opcionalmente sustituidos;n es un número entero que tiene un valor de 1 a 3;m es un número entero que tiene un valor de 1 a 3;...A compound of the formula: wherein R is -NH-C (X2) -NH- (CR13 R14) v -Z; Z is W, HET, optionally substituted C1-10 alkyl, optionally substituted C2-10 alkenyl, or alkynyl Optionally substituted C2-10; X is C (X1) 2, O, N-R18, C = O, or S (O) m '; X1 is hydrogen, halogen, C1-10 alkyl, NR4 R5, C (O) NR4 R5, optionally substituted C 1-10 alkyl, C 1-10 alkoxy, C 1-10 alkoxy substituted with halo, hydroxy, aryl, aryl-C 1-4 alkyl, aryloxy, aryl-C 1-4 alkyl -oxy, heteroaryl, heteroarylalkyl, heterocyclic , heterocyclic-C1-4alkyl or heteroaryl-C1-4alkyl oxy; X2 is = O or = S; A is CH2, C (O) or C (S); R1 is independently selected from hydrogen, halogen, nitro, cyano , C1-10 alkyl substituted with halo, C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxy, C1-10 alkoxy substituted with halo, azido, (CR8 R8) q S (O) t R4, hydroxy, hydroxy- C1-10alkyl, aryl, aryl-C1-4alkyl, aryloxy, aryl-C1-4alkyl -oxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic lico-C1-4alkyl, heteroaryl-C1-4alkyl -oxy, aryl-alkenyl C2-10, heteroaryl-alkenyl C2-10, heterocyclic-alkenyl C2-10, (CR8 R8) q NR4 R5, alkenyl C2-10 - C (O) -NR4 R5, (CR8 R8) q C (O) NR4 R5, (CR8 R8) q C (O) NR4 R10, S (O) 3 H, S (O) 3 R8, (CR8 R8) q C (O) R11, C2-10 alkenyl -C (O) R11, C2-10 alkenyl -C (O) OR11, C (O) R11, (CR8 R8) q C (O) OR12, (CR8 R8) q OC (O) R11, (CR8 R8) q NR4 C (O) R11, (CR8 R8) q-NHS (O) 2 R17 or (CR8 R8) q S (O) 2 NR4 R5, or two residues R1 in common they can form O- (CH2) s -O- or a 5-6 membered saturated or unsaturated ring; and in that aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted; n is an integer having a value of 1 to 3; m is an integer having a value of 1 to 3; ...

CO98003009A 1997-01-23 1998-01-23 ANTAGONISTS OF AN IL-8 RECEPTOR CO4920249A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3599097P 1997-01-23 1997-01-23

Publications (1)

Publication Number Publication Date
CO4920249A1 true CO4920249A1 (en) 2000-05-29

Family

ID=21885958

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98003009A CO4920249A1 (en) 1997-01-23 1998-01-23 ANTAGONISTS OF AN IL-8 RECEPTOR

Country Status (2)

Country Link
CO (1) CO4920249A1 (en)
ZA (1) ZA98519B (en)

Also Published As

Publication number Publication date
ZA98519B (en) 1998-10-23

Similar Documents

Publication Publication Date Title
AR003428A1 (en) DERIVATIVES OF PIRIMIDINDIONA OR TRIAZINDIONA AS ANTAGONIST OF THE ALPHA ADRENERGENIC RECEPTORS, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES.
CO4890843A1 (en) IL-8 RECEPTORS ANTAGONISTS OF IL-8
CO5271716A1 (en) CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED
CO5310550A1 (en) NEW ANTI-INFLAMMATORY ANDROSTAN DERIVATIVE, ITS POLYMORPH, ITS SOLVED CRYSTAL FORMS, PHARMACEUTICAL COMPOSITIONS, PROCESS TO PREPARE IT, INTERMEDIARY
HUP0300616A2 (en) Adamantane derivatives, process for their preparation, their use and pharmaceutical compositions containing them
AR011101A1 (en) ARILSULFONYLAMINOHYDROXYAMIC ACID DERIVED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING IT
ES8401032A1 (en) 1,4-Dihydropyridines, process for their preparation and their application as pharmaceutical preparations.
TR199801594A2 (en) CCR-3 receptor antagonists.
AR002012A1 (en) A COMPOUND, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, ITS USE, METHOD OF THERAPEUTIC TREATMENT, METHOD FOR THE PREPARATION OF THE COMPOUND.
AR032398A1 (en) SULFONAMIDE ESCUARAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND TO PREPARE SUCH COMPOSITION
ES2097174T3 (en) DERIVATIVES OF 2-CICLOHEXAN-1-IL AMINA.
AR023681A1 (en) DERIVATIVES OF TETRAHYDROBENZAZEPINAS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
YU31699A (en) Quinoline and quinazoline compounds useful in treatment of begnin prostatic hyperplazia
CA2239603A1 (en) Quinolines and quinazolines useful in therapy
RU93004675A (en) 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles, their use as antiviral agents, pharmaceutical composition
ES2122258T3 (en) 4-AZAESTEROIDS 15 SUBSTITUTED.
DK0759027T3 (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
AR008331A1 (en) ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CO5200760A1 (en) RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8
MXPA02012569A (en) New substituted phthalides, a process for their preparation and pharmaceutical compositions containing them.
DK489180A (en) PROCEDURE FOR THE PREPARATION OF SECONDARY AMINES
ATE12641T1 (en) AZEPININDOLS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MX9306529A (en) DERIVATIVES OF CONDENSED PYRAZOLE, METHOD TO MANUFACTURE THEM AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM
AR028743A1 (en) DERIVATIVES OF N-TRIAZOLILMETIL-PIPERAZINA WITH ANTAGONIST ACTION OF NEUROQUININE RECEPTORS
CO4920249A1 (en) ANTAGONISTS OF AN IL-8 RECEPTOR